Expression of RBMS3 in Breast Cancer Progression

• Published in: International journal of molecular sciences Vol. 24; no. 3; p. 2866
• Main Authors: Górnicki, Tomasz, Lambrinow, Jakub, Mrozowska, Monika, Romanowicz, Hanna, Smolarz, Beata, Piotrowska, Aleksandra, Gomułkiewicz, Agnieszka, Podhorska-Okołów, Marzena, Dzięgiel, Piotr, Grzegrzółka, Jędrzej
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02.02.2023; MDPI
• Subjects: Apoptosis; Biomarkers; Breast - metabolism; Breast cancer; Breast Neoplasms - metabolism; cancer prevention; carcinogenesis; Carcinoma, Ductal, Breast - pathology; Cell cycle; Cell Line, Tumor; Epithelial cells; epithelial–mesenchymal transition (EMT); Epithelium; ErbB-2 protein; Estrogens; Female; Gene expression; Humans; In vivo methods and tests; Localization; MCF-7 Cells; Medical prognosis; mRNA; Ovarian cancer; Proteins; RNA, Messenger - genetics; RNA-binding protein 3 (RBMS3); RNA-Binding Proteins - metabolism; Statistical analysis; Statistics; Stromal cells; Survival; target discovery; target therapy; Telomerase reverse transcriptase; Trans-Activators - metabolism; Tumor cell lines; epithelial–mesenchymal transition (EMT); target discovery; RNA-binding protein 3 (RBMS3); cancer prevention; carcinogenesis; target therapy
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24032866

The aim of the study was to evaluate the localization and intensity of RNA-binding motif single-stranded-interacting protein 3 (RBMS3) expression in clinical material using immunohistochemical (IHC) reactions in cases of ductal breast cancer (in vivo), and to determine the level of RBMS3 expression at both the protein and mRNA levels in breast cancer cell lines (in vitro). Moreover, the data obtained in the in vivo and in vitro studies were correlated with the clinicopathological profiles of the patients. Material for the IHC studies comprised 490 invasive ductal carcinoma (IDC) cases and 26 mastopathy tissues. Western blot and RT-qPCR were performed on four breast cancer cell lines (MCF-7, BT-474, SK-BR-3 and MDA-MB-231) and the HME1-hTERT (Me16C) normal immortalized breast epithelial cell line (control). The Kaplan-Meier plotter tool was employed to analyze the predictive value of overall survival of expression at the mRNA level. Cytoplasmatic RBMS3 IHC expression was observed in breast cancer cells and stromal cells. The statistical analysis revealed a significantly decreased RBMS3 expression in the cancer specimens when compared with the mastopathy tissues ( < 0.001). An increased expression of RBMS3 was corelated with HER2(+) cancer specimens ( < 0.05) and ER(-) cancer specimens ( < 0.05). In addition, a statistically significant higher expression of RBMS3 was observed in cancer stromal cells in comparison to the control and cancer cells ( < 0.0001). The statistical analysis demonstrated a significantly higher expression of mRNA in the SK-BR-3 cell line compared with all other cell lines ( < 0.05). A positive correlation was revealed between the expression of RBMS3, at both the mRNA and protein levels, and longer overall survival. The differences in the expression of RBMS3 in cancer cells (both in vivo and in vitro) and the stroma of breast cancer with regard to the molecular status of the tumor may indicate that RBMS3 could be a potential novel target for the development of personalized methods of treatment. RBMS3 can be an indicator of longer overall survival for potential use in breast cancer diagnostic process.